Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and random...Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and randomized into two groups according to the random number table in a ratio of 3：1, with 8 cases eventually dropping out. The symptoms, signs, liver function markers, blood lipids, iconographic indices and clinical comprehensive efficacy after a 12-week treatment course were assessed in 101 patients treated with TZYGD in the treated group and 29 patients treated with Thiola in the control group. Results： The total effective rate in the treated group and the control group was 81.19% and 68.97%, respectively, showing a significant difference between the two groups with the former being significantly higher than the latter （P〈0.05）. Moreover, the improvements in the symptoms, signs, liver function, blood lipids and iconographic indices in the treated group were favorable with no serious adverse reactions. Conclusion： TZYGD is effective and highly safe in treating non-alcoholic fatty liver.展开更多
文摘Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and randomized into two groups according to the random number table in a ratio of 3：1, with 8 cases eventually dropping out. The symptoms, signs, liver function markers, blood lipids, iconographic indices and clinical comprehensive efficacy after a 12-week treatment course were assessed in 101 patients treated with TZYGD in the treated group and 29 patients treated with Thiola in the control group. Results： The total effective rate in the treated group and the control group was 81.19% and 68.97%, respectively, showing a significant difference between the two groups with the former being significantly higher than the latter （P〈0.05）. Moreover, the improvements in the symptoms, signs, liver function, blood lipids and iconographic indices in the treated group were favorable with no serious adverse reactions. Conclusion： TZYGD is effective and highly safe in treating non-alcoholic fatty liver.
